This Article Full Text (PDF) All Versions of this Article: 1076029607308863v1 15/2/225    most recent References Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Alsayegh, F. Articles by Mousa, S. A. Search for Related Content PubMed PubMed Citation Articles by Alsayegh, F. Articles by Mousa, S. A. Pubmed/NCBI databases Substance via MeSH Social Bookmarking                         What's this?

Use of Recombinant Activated Factor VII to Arrest Uncontrolled Bleeding: A Case Series

Faculty of Medicine, Kuwait University, and Department of Medicine, Mubarak Al-Kabeer Hospital

Aisha Fakeir, MD

Department of Laboratory Medicine, Al-Jahra Hospital

Salah Alhumood, MD

Department of Laboratory Medicine, Al-Sabah Hospital

Kefaya Abdumalek, MD

Intensive Care Unit, Al-Amiri Hospital

Hatem Matar, MD

Maternity Department, Ahmadi Hospital and Kuwait Oil Company Hospital

Isaac Samaul, MD

Maternity Department, Ahmadi Hospital and Kuwait Oil Company Hospital

Narayanan Nampoory, MD

Department of Medicine, Mubarak Al-Kabeer Hospital and Hamed Al-Essa Organ Transplant Centre

Housam Kabalawi, MD

Department of Medicine, Mubarak Al-Kabeer Hospital Kuwait

Shaker A. Mousa, PhD

The Pharmaceutical Research Institute at Albany, Albany College of pharmacy, New York, mousas{at}acp.edu

A retrospective analysis is described to assess the effects of using recombinant activated factor VII to control bleeding in a series of patients who had failed to respond to conventional hemostatic measures. In all, 18 patients (aged 16-65 years) with a range of conditions resulting in bleeding refractory to conventional methods of control were treated with recombinant activated factor VII (60-120 µg/kg; 1-4 doses). The effects of recombinant activated factor VII on bleeding were noted together with the patients’ transfusion requirements and hematological parameters. Administration of recombinant activated factor VII successfully stopped bleeding in 17 of the 18 patients. Therapy with recombinant activated factor VII significantly decreased transfusion requirements for packed red blood cells, fresh frozen plasma, platelets, and cryoprecipitate compared with pretreatment values along with significant improvement in hemostasis. In various serious bleeding situations, treatment with recombinant activated factor VII may effectively arrest bleeding, which has remained refractory to conventional methods of control.

Key Words: uncontrolled bleeding • hemostasis • rFVIIa • recombinant activated factor VII • surgery • trauma

This version was published on April 1, 2009

Clinical and Applied Thrombosis/Hemostasis, Vol. 15, No. 2, 225-232 (2009)
DOI: 10.1177/1076029607308863


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?